Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tarceva erlotinib: Complete Phase IIIb enrollment

DNA said ROG expects to complete enrollment of 850 patients in the Phase

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE